[1]黄 涛.含铋剂的四联疗法治疗消化性溃疡患者的临床疗效及对溃疡愈合、炎症因子的影响[J].医学信息,2024,37(16):55-58.[doi:10.3969/j.issn.1006-1959.2024.16.011]
　HUANG Tao.Clinical Efficacy of Bismuth-containing Quadruple Therapy in the Treatment of Patientswith Peptic Ulcer and its Effect on Ulcer Healing and Inflammatory Factors[J].Journal of Medical Information,2024,37(16):55-58.[doi:10.3969/j.issn.1006-1959.2024.16.011]
点击复制

含铋剂的四联疗法治疗消化性溃疡患者的临床疗效及对溃疡愈合、炎症因子的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年16期
页码:
55-58
栏目:
论著
出版日期:
2024-08-15

文章信息/Info

Title:
Clinical Efficacy of Bismuth-containing Quadruple Therapy in the Treatment of Patientswith Peptic Ulcer and its Effect on Ulcer Healing and Inflammatory Factors
文章编号:
1006-1959（2024）16-0055-04
作者:
黄 涛
江西省德兴市人民医院消化内科，江西 德兴 334200
Author(s):
HUANG Tao
Department of Gastroenterology,Jiangxi Dexing Hospital,Dexing 334200,Jiangxi,China
关键词:
消化性溃疡; 铋剂; 四联疗法; 溃疡愈合; 不良反应; 生活质量
Keywords:
Peptic ulcer; Bismuthagent; Quadruple therapy; Ulcer healing; Adverse reactions; Quality of life
分类号:
R574.1
DOI:
10.3969/j.issn.1006-1959.2024.16.011
文献标志码:
A
摘要:
目的 研究含铋剂四联疗法治疗消化性溃疡患者的临床疗效及对其溃疡愈合、炎症因子的影响。方法 选取2020年5月-2023年5月江西省德兴市人民医院消化内科收治的60例消化性溃疡患者作为研究对象，行随机数字表法分为三联组（30例）和四联组（30例）。三联组采用三联疗法（雷贝拉唑+阿莫西林+克拉霉素），四联组应用含铋剂四联疗法（胶体果胶铋+雷贝拉唑+阿莫西林+克拉霉素），比较两组临床疗效、溃疡愈合情况（溃疡直径、胃黏膜损伤Lanza评分）、炎症因子[白细胞介素2（IL-2）、白细胞介素6（IL-6）]、不良反应、预后情况[消化性溃疡量表（QLICD-PU）、胃溃疡复发率]。结果 四联组治疗总有效率为96.67%，高于三联组的80.00%（P＜0.05）；两组治疗后溃疡直径、胃黏膜损伤Lanza评分均小于治疗前，且四联组溃疡直径、胃黏膜损伤Lanza评分小于三联组（P＜0.05）；两组治疗后IL-2、IL-6水平均低于治疗前，且四联组IL-2、IL-6水平低于三联组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）；两组治疗后QLICD-PU评分高于治疗前，且四联组QLICD-PU评分高于三联组（P＜0.05）；四联组胃溃疡复发率低于三联组（P＜0.05）。结论 含铋剂四联疗法治疗消化性溃疡的效果确切，可促进溃疡愈合，缓解体内炎症，有利于预后生活质量的改善，且复发率低，用药安全性佳。
Abstract:
Objective To study the clinical efficacy of bismuth-containing quadruple therapy in the treatment of peptic ulcer patients and its effect on ulcer healing and inflammatory factors.Methods A total of 60 patients with peptic ulcer admitted to the Department of Gastroenterology, Jiangxi Dexing Hospital from May 2020 to May 2023 were selected as the research objects. They were divided into triple group (30 patients) and quadruple group (30 patients) by random number table method. The triple group was treated with triple therapy (rabeprazole+amoxicillin+clarithromycin), and the quadruple group was treated with bismuth-containing quadruple therapy (colloidal bismuth pectin+rabeprazole+amoxicillin+clarithromycin). The clinical efficacy, ulcer healing (ulcer diameter, Lanza score of gastric mucosal injury), inflammatory factors [interleukin-2 (IL-2), interleukin-6 (IL-6)], adverse reactions, prognosis [peptic ulcer scale (QLICD-PU), gastric ulcer recurrence rate] were compared between the two groups.Results The total effective rate of treatment in the quadruple group was 96.67%, which was higher than 80.00% in the triple group (P<0.05). After treatment, the ulcer diameter and Lanza score of gastric mucosal injury in the two groups were lower than those before treatment, and the ulcer diameter and Lanza score of gastric mucosal injury in the quadruple group were lower than those in the triple group (P<0.05). After treatment, the levels of IL-2 and IL-6 in the two groups were lower than those before treatment, and the levels of IL-2 and IL-6 in the quadruple group were lower than those in the triple group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The QLICD-PU score of the two groups after treatment was higher than that before treatment, and the QLICD-PU score of the quadruple group was higher than that of the triple group (P<0.05). The recurrence rate of gastric ulcer in quadruple group was lower than that in triple group (P<0.05).Conclusion Bismuth-containing quadruple therapy is effective in the treatment of peptic ulcer, which can promote ulcer healing, relieve inflammation in the body, improve the quality of life of prognosis, and has low recurrence rate and good drug safety.

参考文献/References:

[1]杨小红,杨海涛,刘超,等.含阿莫西林克拉维酸钾的铋剂四联方案治疗幽门螺杆菌感染致慢性胃炎的有效性及安全性观察[J].药物评价研究,2022,45(9):1863-1869.[2]齐涛,钱丹烨,朱黎明.不同抗生素组合的含铋剂四联方案根除幽门螺杆菌的疗效分析[J].国际消化病杂志,2022,42(3):200-203.[3]刘香吉.铋剂四联对胃溃疡患者血清炎性因子、H.pylori根治率及细胞免疫指标的影响[J].河北医药,2021,43(23):3637-3639.[4]林五连,何小建,李海涛,等.安妥沙星铋剂四联疗法根除幽门螺杆菌疗效分析[J].胃肠病学,2021,26(2):71-75.[5]钟雄平.含铋剂四联疗法根除幽门螺杆菌感染的临床疗效分析[J].山西医药杂志,2020,49(19):2645-2646.[6]李理总,刘彤,何晓静,等.含质子泵抑制剂的铋剂四联方案根除幽门螺杆菌的成本-效果分析[J].实用药物与临床,2020,23(4):349-352.[7]朱虹,时昭红,张书,等.含铋剂四联疗法对幽门螺旋杆菌感染患者血清炎性因子及免疫功能的影响[J].中华医院感染学杂志,2020,30(1):77-81.[8]樊文静,张振宇,杨景玉,等.含铋剂四联疗法治疗幽门螺旋杆菌阳性胃溃疡的临床效果[J].广西医学,2019,41(18):2306-2308.[9]张启宇,李岩.三种含铋剂四联疗法根除幽门螺杆菌的疗效分析[J].胃肠病学和肝病学杂志,2019,28(8):886-889.[10]闫小妮,屈彦,姚晚侠,等.铋剂四联疗法联合不同药物对幽门螺杆菌感染的疗效[J].中国微生态学杂志,2019,31(8):910-914.[11]李彬龙,和水祥,李颜霞.两种方案根除消化性溃疡和慢性胃炎患者幽门螺杆菌的疗效对比[J].西部医学,2019,31(7):1053-1056.[12]Pellicano R,Zagari RM,Zhang S,et al.Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018[J].Minerva Gastroenterol Dietol,2018,64(3):310-321.[13]陈兆夷,黄志刚,邓衍部,等.含铋剂四联疗法治疗慢性胃溃疡伴幽门螺杆菌感染患者的临床疗效研究[J].中华生物医学工程杂志,2019,25(6):763-767.[14]梅玲华,贺兆平,杨永宏,等.含铋剂四联疗法对幽门螺杆菌阳性小儿消化性溃疡的疗效观察[J].现代消化及介入诊疗,2019,24(4):395-398.[15]刘春,方之洪.四联疗法与传统三联疗法治疗小儿胃炎合并消化性溃疡的临床疗效对比研究[J].现代消化及介入诊疗,2019,24(3):268-270.[16]王一倩,张嫣,李小雯.含铋剂的兰索拉唑四联疗法治疗Hp阳性慢性胃炎的疗效观察[J].贵州医药,2018,42(12):1444-1445.[17]时玉华,王丽娜,史增辉,等.混合疗法与铋剂四联方案治疗H.pylori阳性消化性溃疡的疗效比较[J].河北医药,2019,41(13):1981-1984.[18]张艳,陈爽,杨秀金,等.四种含铋剂四联方案根除幽门螺杆菌的疗效比较[J].海南医学,2018,29(22):3116-3118.[19]刘辉,何春艳.铋剂四联疗法对慢性胃炎患者临床症状及胃泌素的影响[J].贵州医药,2018,42(1):54-57.[20]Macías-García F,Bastón-Rey I,de la Iglesia-García D,et al.Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial[J].Helicobacter,2019,24(1):e12546.

相似文献/References:

[1]夏 铭,张正坤,曾海龙,等.四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析[J].医学信息,2018,31(11):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
　XIA Ming,ZHANG Zheng-kun,ZENG Hai-long,et al.Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer[J].Journal of Medical Information,2018,31(16):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
[2]高华初.泮托拉唑治疗消化性溃疡合并上消化道出血的临床价值评价[J].医学信息,2018,31(22):153.[doi:10.3969/j.issn.1006-1959.2018.22.045]
　GAO Hua-chu.Clinical Value of Pantoprazole in the Treatment of Peptic Ulcer Complicated with Upper Gastrointestinal Bleeding[J].Journal of Medical Information,2018,31(16):153.[doi:10.3969/j.issn.1006-1959.2018.22.045]
[3]张宏程.磷酸铝凝胶联合奥美拉唑治疗消化性溃疡的临床疗效观察[J].医学信息,2019,32(02):150.[doi:10.3969/j.issn.1006-1959.2019.02.044]
　ZHANG Hong-cheng.Clinical Efficacy of Aluminum Phosphate Gel Combined with Omeprazole in the Treatment of Peptic Ulcer[J].Journal of Medical Information,2019,32(16):150.[doi:10.3969/j.issn.1006-1959.2019.02.044]
[4]于 萍.国内消化性溃疡药物治疗现状[J].医学信息,2019,32(11):42.[doi:10.3969/j.issn.1006-1959.2019.11.012]
　YU Ping.Current Status of Domestic Peptic Ulcer Drug Treatment[J].Journal of Medical Information,2019,32(16):42.[doi:10.3969/j.issn.1006-1959.2019.11.012]
[5]谢迎新.复方嗜酸乳杆菌联合常规四联疗法治疗幽门螺旋杆菌感染消化性溃疡的疗效[J].医学信息,2020,33(02):138.[doi:10.3969/j.issn.1006-1959.2020.02.040]
　XIE Ying-xin.Effect of Compound Lactobacillus Acidophilus Combined with Conventional Quadruple Therapy in the Treatment of Peptic Ulcer Caused by Helicobacter Pylori Infection[J].Journal of Medical Information,2020,33(16):138.[doi:10.3969/j.issn.1006-1959.2020.02.040]
[6]周雯雯.法莫替丁与奥美拉唑钠治疗儿童消化性溃疡的效价[J].医学信息,2020,33(17):146.[doi:10.3969/j.issn.1006-1959.2020.17.042]
　ZHOU Wen-wen.The Potency of Famotidine and Omeprazole Sodium in the Treatment of Peptic Ulcer in Children[J].Journal of Medical Information,2020,33(16):146.[doi:10.3969/j.issn.1006-1959.2020.17.042]
[7]刘敏芝,李运泽.幽门螺杆菌的治疗现状[J].医学信息,2021,34(15):35.[doi:10.3969/j.issn.1006-1959.2021.15.010]
　LIU Min-zhi,LI Yun-ze.Current Status of Treatment of Helicobacter Pylori[J].Journal of Medical Information,2021,34(16):35.[doi:10.3969/j.issn.1006-1959.2021.15.010]
[8]刘少玲,谢梅娟,谭雪群,等.基于网络药理学方法研究柴胡疏肝散抗消化性溃疡的作用机制[J].医学信息,2022,35(09):22.[doi:10.3969/j.issn.1006-1959.2022.09.006]
　LIU Shao-ling,XIE Mei-juan,TAN Xue-qun,et al.Study on the Mechanism of Chaihu Shugan Powder for Anti-peptic Ulcer Based on Network Pharmacology[J].Journal of Medical Information,2022,35(16):22.[doi:10.3969/j.issn.1006-1959.2022.09.006]
[9]周海玲,丁 劲,葸英博,等.基于CiteSpace的消化性溃疡护理热点及前沿趋势分析[J].医学信息,2022,35(16):33.[doi:10.3969/j.issn.1006-1959.2022.16.007]
　ZHOU Hai-ling,DING Jin,XI Ying-bo,et al.Analysis of Hot Spots and Frontier Trends of Peptic Ulcer Nursing Based on CiteSpace[J].Journal of Medical Information,2022,35(16):33.[doi:10.3969/j.issn.1006-1959.2022.16.007]
[10]李光明,曾军红,郭香莲.奥曲肽联合泮托拉唑治疗老年消化性溃疡合并上消化道出血的疗效及对凝血功能和炎症因子的影响[J].医学信息,2022,35(22):99.[doi:10.3969/j.issn.1006-1959.2022.22.020]
　LI Guang-ming,ZENG Jun-hong,GUO Xiang-lian.Efficacy of Octreotide Combined with Pantoprazole in the Treatment of Elderly Peptic Ulcer Complicated with Upper Gastrointestinal Hemorrhage and its Effect on Coagulation Function and Inflammatory Factors[J].Journal of Medical Information,2022,35(16):99.[doi:10.3969/j.issn.1006-1959.2022.22.020]

更新日期/Last Update: 1900-01-01